Related Experiment Video
Updated: Aug 9, 2026

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
Alternative mechanisms of action of anti-oestrogens
A A Colletta1, J R Benson, M Baum
1Section of Academic Surgery, Royal Marsden Hospital, London, UK.
Abstract:
The molecular mechanism of action of anti-oestrogens such as tamoxifen appears to be a complex mixture of antagonism of the mitogenic action of oestradiol at the level of the oestrogen receptor, plus a range of other activities from enzyme inhibition to growth factor modulation. This article will concentrate on two specific areas: 1) the inhibition of protein kinase C and calmodulin-dependent cAMP phosphodiesterase; and 2) the regulation by tamoxifen of peptide regulators of breast cancer epithelial cell growth such as insulin-like growth factor I (IGF I) and transforming growth factor beta (TGF-beta). The elucidation of these mechanisms is potentially important in the treatment and chemoprevention of breast cancer-the quantitative contribution of each individual mechanism of the overall antineoplastic action of anti-oestrogens is central to developing new and possibly more effective anti-oestrogens and optimizing strategies for their use.
Insights
Tamoxifen
Area of Science:
- Oncology
- Molecular Pharmacology
Background:
- Anti-oestrogens, like tamoxifen, exhibit complex mechanisms beyond oestrogen receptor antagonism.
- Their action involves enzyme inhibition and growth factor modulation, crucial for breast cancer treatment.
Purpose of the Study:
- To investigate tamoxifen's inhibition of protein kinase C and calmodulin-dependent cAMP phosphodiesterase.
- To examine tamoxifen's regulation of peptide growth regulators, including insulin-like growth factor I (IGF-I) and transforming growth factor beta (TGF-β), in breast cancer cells.
Main Methods:
- Focuses on two key areas: enzyme inhibition and growth factor regulation.
- Examines the molecular targets and pathways affected by tamoxifen.
Main Results:
- Tamoxifen inhibits protein kinase C and calmodulin-dependent cAMP phosphodiesterase.
- Tamoxifen modulates peptide growth regulators like IGF-I and TGF-β in breast cancer epithelial cells.
Conclusions:
- Understanding these mechanisms is vital for breast cancer treatment and chemoprevention.
- Quantifying individual mechanisms aids in developing improved anti-oestrogens and optimizing therapeutic strategies.
Related Concept Videos
Oogenesis
Secondary Messengers in Hormone Action
Many hormones bind to transmembrane G protein-coupled receptors that connect to regulatory G proteins. These G proteins can then activate enzymes such as adenylyl cyclase or phospholipase C. Adenylyl cyclase converts ATP to cAMP, activating...
Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...

